Literature DB >> 21234125

Mastering a mediator: blockade of CCN-2 shows early promise in human diabetic kidney disease.

Stephen M Twigg.   

Abstract

In diabetes complications, CCN-2 (known originally as CTGF) has been implicated in diabetic nephropathy both as a marker and a mediator of disease. This commentary addresses CCN-2 in diabetic nephropathy, in the context of the recent publication of the first human study to inhibit CCN-2 bioactivity in diabetic kidney disease.

Entities:  

Keywords:  Chronic kidney disease; Connective tissue growth factor; Diabetic nephropathy; Humanised antibody

Year:  2010        PMID： 21234125      PMCID： PMC2995133          DOI： 10.1007/s12079-010-0102-2

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN： 1873-9601            Impact factor:   5.782


  74 in total

Review 1.  The antiglobulin response to therapeutic antibodies.

Authors:  J D Isaacs
Journal:  Semin Immunol       Date:  1990-11       Impact factor: 11.130

2.  Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes.

Authors:  Bing Wang; Rickey E Carter; Miran A Jaffa; Sashidhar Nakerakanti; Daniel Lackland; Maria Lopes-Virella; Maria Trojanowska; Louis M Luttrell; Ayad A Jaffa
Journal:  J Med Genet       Date:  2010-06       Impact factor: 6.318

3.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Authors:  Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

4.  Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria.

Authors:  Sharon G Adler; Sherwyn Schwartz; Mark E Williams; Carlos Arauz-Pacheco; Warren K Bolton; Tyson Lee; Dongxia Li; Thomas B Neff; Pedro R Urquilla; K Lea Sewell
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-03       Impact factor: 8.237

5.  Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy.

Authors:  N A Wahab; N Yevdokimova; B S Weston; T Roberts; X J Li; H Brinkman; R M Mason
Journal:  Biochem J       Date:  2001-10-01       Impact factor: 3.857

6.  Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice.

Authors:  Peggy Roestenberg; Frans A van Nieuwenhoven; Jaap A Joles; Claudia Trischberger; Paula P Martens; Noelynn Oliver; Jan Aten; Jo W Höppener; Roel Goldschmeding
Journal:  Am J Physiol Renal Physiol       Date:  2005-12-27

7.  Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it?

Authors:  Roger M Mason
Journal:  J Cell Commun Signal       Date:  2009-02-14       Impact factor: 5.782

Review 8.  The extracellular matrix in diabetic nephropathy.

Authors:  F N Ziyadeh
Journal:  Am J Kidney Dis       Date:  1993-11       Impact factor: 8.860

9.  Renal connective tissue growth factor correlates with glomerular basement membrane thickness and prospective albuminuria in a non-human primate model of diabetes: possible predictive marker for incipient diabetic nephropathy.

Authors:  Sally E Thomson; Susan V McLennan; Paul D Kirwan; Scott J Heffernan; Annemarie Hennessy; Dennis K Yue; Stephen M Twigg
Journal:  J Diabetes Complications       Date:  2008-04-16       Impact factor: 2.852

10.  Getting to the heart of the matter: CCN2 plays a role in cardiomyocyte hypertrophy.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2009-08-24       Impact factor: 5.782
View more
  6 in total

1.  CCN-2 is up-regulated by and mediates effects of matrix bound advanced glycated end-products in human renal mesangial cells.

Authors:  Xiaoyu Wang; Susan V McLennan; Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2011-06-02       Impact factor: 5.782

Review 2.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

3.  CCN2: a bona fide target for anti-fibrotic drug intervention.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2011-03-06       Impact factor: 5.782

4.  CCN3: a novel anti-fibrotic treatment in end-stage renal disease?

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2012-03-16       Impact factor: 5.782

Review 5.  Regulation and bioactivity of the CCN family of genes and proteins in obesity and diabetes.

Authors:  Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2018-02-06       Impact factor: 5.782

6.  Gremlin induces cell proliferation and extra cellular matrix accumulation in mouse mesangial cells exposed to high glucose via the ERK1/2 pathway.

Authors:  Haixia Huang; Haiying Huang; Ying Li; Maodong Liu; Yonghong Shi; Yanqing Chi; Tao Zhang
Journal:  BMC Nephrol       Date:  2013-02-11       Impact factor: 2.388
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.